



ASX Announcement

September 15, 2021

CHIMERIC THERAPEUTICS APPOINTS RANGE OF EXPERTS TO CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the appointment of three highly regarded cell therapy experts to the Company’s Cellular Immunotherapy Scientific Advisory Board (CI-SAB).

With a growing pipeline of cellular immunotherapies Chimeric recently initiated a new Cellular Immunotherapy Scientific Advisory Board (CI-SAB) to ensure Chimeric’s development is informed by the latest scientific research as well as expert practical and clinical perspectives.

Dr Eric Smith – Dana-Farber Cancer Institute

Dr Smith is currently the Director of Translational Research, Immune Effector Cell Therapies, the head of the Eric Smith Lab for Synthetic Biology and Cellular Engineering at the Dana-Farber Cancer Institute and a member of the Faculty of Medicine at the Harvard Medical School in Boston, Massachusetts.

Dr Smith is a highly respected translational researcher that specializes in the discovery and development of cellular immunotherapies with a focus in blood cancers. Dr Smith utilizes the latest advances in gene engineering and cellular manipulation to design and screen novel cellular therapy strategies which he then works in collaboration to rapidly advance to clinic.

Dr Smith spent the early part of his career in New York where he earned his MD and PhD (Genetics and Genomic Sciences) from the Mount Sinai School of Medicine, before moving to Memorial Sloan Kettering Cancer Center (MSKCC) for his medical oncology fellowship and further research training. Dr Smith went on to serve as faculty and Director of Translational Development at the MSKCC Cellular Therapeutics Center before joining the Harvard Medical community at the Dana Farber Cancer Institute in mid-2020.

Dr Smith's pre-clinical work has resulted in nine awarded or pending patents, multiple products stemming from his lab work have been translated to the clinic and he is an author of many seminal publications in the field.

Dr David G Maloney – Fred Hutchinson Cancer Research Center

Dr Maloney is a renowned clinician-scientist who has been at the forefront of cellular therapy research and development. Dr Maloney has been a clinical investigator in over 15 cellular therapy clinical trials ranging from phase 1, first in human trials through to commercially



approved CAR T cell therapies.

Dr Maloney has amassed greater than 265 publications in peer-reviewed journals and has received the Presidential Award from the International Society for Biology Therapy of Cancer (now the Society for Immunotherapy of Cancer). He received his MD and PhD in cancer biology from Stanford University, completed a fellowship in oncology at Stanford and in 1994 joined the faculties of Fred Hutchinson Cancer Research Center and the University of Washington where he is currently a Member in the Clinical Research Division and a Professor of Medicine in the Division of Oncology. He is also the Medical Director for Cellular Immunotherapy and holds the Leonard and Norma Klorfine Endowed Chair for Clinical Research.

Dr Michael R Bishop – University of Chicago

Dr Bishop is a pioneer and widely recognized expert in cellular therapy research and patient care, with a focus on leukemias and lymphomas. Dr Bishop has served as an investigator for multiple clinical trials investigating novel cellular immunotherapies, including phase 1 clinical trials for autologous and allogeneic CAR T and TCR products.

Dr Bishop is an active contributor to medical literature, authoring more than 200 peer-reviewed articles, in addition to more than 35 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including *Biology of Blood and Marrow Transplantation*.

Dr Bishop previously served as the Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago and as a senior investigator and the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.

Commenting on the appointments, Chimeric’s CEO and Managing Director Jennifer Chow said:

“We are honored to have these outstanding individuals joining our scientific advisory board. They bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field. As we move into our next phase of growth we expect the insights and guidance they will bring to the table to be of great value to Chimeric.”

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.



To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.

Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
P: +9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au